Pharma major Venus Remedies Ltd on Monday (January 20) said it has successfully renewed its European Good Manufacturing Practices (GMP) certification from Infarmed, Portugal’s national authority of medicines and health products.
CompanyValueChange%Change
The certification covers the company’s manufacturing facility for cephalosporin, carbapenem, and lyophilized injectable oncology formulations, reaffirming its commitment to delivering world-class pharmaceutical products to the European market.
“Covering Oncology (Liquid commitment to our manufacturing facility for Cephalosporin, Carbapenem, and Lyophilized Injectable) formulations, this milestone underscores our unwavering delivering world-class pharmaceutical products to the European market,” Venus Remedies said in a regulatory filing.
Also Read: Venus Remedies surges nearly 8% on authorisation to market lung cancer treatment drug in Philippines
Having initially received EU GMP certification in 2007, Venus Remedies has maintained a strong foothold in Europe for over 15 years. The company is among the leading exporters of meropenem outside India and holds multiple marketing authorisations across the region.
“Having received our first EU GMP certification in 2007, Venus Remedies has consistently maintained a robust presence in the European market for over 15 years. As one of the leading exporters of Meropenem outside India and with multiple marketing authorizations across Europe, we remain a trusted partner in providing high-quality antibiotics and oncology products,” Venus Remedies said.
Also Read: Venus Remedies gains after receiving good manufacturing certification from Moldova health ministry
Shares of Venus Remedies Ltd ended at ₹296.20, down by ₹3.35, or 1.12%, on the BSE.
(Edited by : Shoma Bhattacharjee)
Source link : http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=678e6089bbff41b1badad211a6514efb&url=https%3A%2F%2Fwww.cnbctv18.com%2Fmarket%2Fstocks%2Fvenus-remedies-share-price-announces-successful-renewal-of-its-eu-gmp-certification-oncology-drugs-19543332.htm&c=4512151924643440828&mkt=en-us
Author :
Publish date : 2025-01-20 05:13:00
Copyright for syndicated content belongs to the linked Source.
